Isis Pharmaceuticals (ISIS) 46.06 $ISIS

Isis Pharmaceuticals Shares Up 40.9% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Fri Oct 31, 10:59AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 40.92% as of today's recent price of $46.68.
ISIS: 46.06 (+0.18)

Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 2.96 (-0.05), ACAD: 27.70 (-0.35), HALO: 9.62 (+0.01), ISIS: 46.06 (+0.18), NSPH: 0.44 (unch)

Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
PR Newswire - Fri Oct 31, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
ISIS: 46.06 (+0.18)

Critical Alerts For AT&T, SolarWinds, Whole Foods Market, FireEye and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Thu Oct 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for T, SWI, WFM, FEYE and ISIS.
WFM: 39.33 (+0.56), T: 34.84 (+0.33), SWI: 47.55 (-0.04), FEYE: 33.99 (+0.36), ISIS: 46.06 (+0.18)

Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
PR Newswire - Thu Oct 30, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at 8:30 a.m. ET in Boston, MA.
ISIS: 46.06 (+0.18)

'Mad Money' Lightning Round: Stay Away From Applied Materials
at The Street - Thu Oct 30, 5:00AM CDT
Cramer prefers Isis Pharmaceuticals to Pfizer and Kinder Morgan to El Paso Pipeline Partners.
KMI: 38.70 (+0.16), EPB: 40.65 (+0.10), ISIS: 46.06 (+0.18), PFE: 29.95 (+0.11), AMAT: 22.09 (+0.75), INVN: 16.21 (+0.54), IGT: 16.39 (+0.20), REGN: 393.72 (+0.92), CVRR: 24.24 (-0.10), CELG: 107.09 (+0.15)

Jim Cramer's 'Mad Money' Recap: Where to Find Bargains Created by the Fed
at The Street - Wed Oct 29, 7:12PM CDT
With the Federal Reserve finally ending its bond buying, there are many stocks that are ready to be bought, not sold, on any Fed-induced weakness, Cramer says.
KMI: 38.70 (+0.16), ETN: 68.39 (+1.62), FB: 74.99 (+0.88), PFE: 29.95 (+0.11), INVN: 16.21 (+0.54), WDC: 98.37 (+3.18), HPQ: 35.88 (+0.56), CVRR: 24.24 (-0.10), CELG: 107.09 (+0.15), EPB: 40.65 (+0.10), ISIS: 46.06 (+0.18), IBM: 164.40 (+0.05), AMAT: 22.09 (+0.75), GOOGL: 567.87 (+7.60), TWTR: 41.47 (-0.33), MSFT: 46.95 (+0.90), IGT: 16.39 (+0.20), REGN: 393.72 (+0.92), PII: 150.86 (+2.30), BABA: 98.60 (-0.13)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 46.93 (-0.54), RICE: 26.43 (+1.21), GS: 189.99 (+3.02), FEYE: 33.99 (+0.36), ISIS: 46.06 (+0.18), CYBR: 35.28 (+0.57), GNC: 41.57 (-1.33), HAL: 55.14 (+1.22), EOG: 95.05 (+2.83), AGIO: 84.03 (-0.34), FTNT: 26.05 (+0.31)

Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 54.22 (-0.58), FEYE: 33.99 (+0.36), CYBR: 35.28 (+0.57), FB: 74.99 (+0.88), GNC: 41.57 (-1.33), HAL: 55.14 (+1.22), AGCO: 44.31 (+0.36), BWLD: 149.28 (-0.76), MAS: 22.07 (+0.27), YHOO: 46.05 (+0.42), WHR: 172.05 (+1.50), VSI: 46.93 (-0.54), SAVE: 73.11 (+2.21), RICE: 26.43 (+1.21), GS: 189.99 (+3.02), PH: 127.03 (+2.36), ISIS: 46.06 (+0.18), CMI: 146.18 (+1.56), EOG: 95.05 (+2.83), AGIO: 84.03 (-0.34), TWTR: 41.47 (-0.33), FTNT: 26.05 (+0.31), BABA: 98.60 (-0.13)

Regulus Announces Pricing of Public Offering of Common Stock
PR Newswire - Tue Oct 28, 7:10PM CDT
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the pricing of an underwritten public offering of 5,294,118 shares of its common stock at a price to the public of $17.00 per share. 4,411,765 shares are being sold by Regulus and 882,353 shares are being sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. (NASDAQ: ISIS). Regulus and Isis have granted the underwriters a 30-day option to purchase up to an additional 794,117 shares of common stock in the aggregate. The offering is expected to close on or about November 3, 2014, subject to customary closing conditions. The net proceeds to Regulus from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $69.8 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus will not receive any proceeds from the sale of the shares of common stock by Isis. Regulus anticipates using the net proceeds from the offering to fund preclinical and clinical development of its clinical candidates, RG-101 and RG--012, and its other initial microRNA development candidates, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes.
ISIS: 46.06 (+0.18), DB: 31.32 (+0.55), RGLS: 19.96 (+1.66)

Isis Pharmaceuticals Shares Up 27.2% Since SmarTrend's Buy Recommendation (ISIS)
Comtex SmarTrend(R) - Fri Oct 24, 9:43AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 27.20% as of today's recent price of $42.13.
ISIS: 46.06 (+0.18)

24.5% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Oct 17, 9:21AM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 2 months, Isis Pharmaceuticals has returned 24.50% as of today's recent price of $41.24.
ISIS: 46.06 (+0.18)

Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Isis Pharmaceuticals (ISIS) announced positive results from phase II studies on ISIS-SMNRx.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ISIS: 46.06 (+0.18), LGND: 55.27 (+0.90)

Jim Cramer's Top Stock Picks: ISIS KMB PG MNK
at The Street - Sat Oct 11, 5:00AM CDT
Cramer sees better times ahead for Isis Pharmaceuticals and is a big fan of Kimberly-Clark.
MNK: 92.18 (-0.65), ISIS: 46.06 (+0.18), KMB: 114.27 (+0.65), PG: 87.27 (+0.33)

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 10, 6:59PM CDT
From JPMorgan to General Electric, Cramer says he'll be all over earnings next week.
MNK: 92.18 (-0.65), GE: 25.81 (+0.14), HON: 96.12 (+0.53), C: 53.53 (+0.38), KMB: 114.27 (+0.65), MCHP: 43.11 (+2.02), FMC: 57.35 (-0.77), WFC: 53.09 (+0.63), CSX: 35.63 (+0.34), INTC: 34.01 (+1.43), NFLX: 392.77 (+13.76), ISIS: 46.06 (+0.18), JPM: 60.48 (+1.09), ONVO: 6.54 (+0.11), EXPE: 84.97 (+4.24), PG: 87.27 (+0.33), PPG: 203.69 (+11.34)

Uptrend Call Working As Isis Pharmaceuticals Stock Rises 12.5% (ISIS)
Comtex SmarTrend(R) - Thu Oct 09, 4:53PM CDT
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 2 months, Isis Pharmaceuticals has returned 12.45% as of today's recent price of $37.25.
ISIS: 46.06 (+0.18)

Isis Pharmaceuticals earns USD18m for the development of its ISIS-TTR Rx double-blind, placebo-controlled, international study in FAP patients
M2 - Thu Oct 09, 9:14AM CDT
Novel drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Thursday the receipt of USD18m milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
ISIS: 46.06 (+0.18), GSK: 45.49 (+0.35)

Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
PR Newswire - Thu Oct 09, 6:00AM CDT
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned an $18 million milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
ISIS: 46.06 (+0.18), GSK: 45.49 (+0.35)

Critical Alerts For petroleo brasileiro, Herbalife, Micron, FireEye and Isis Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Oct 07, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PBR, HLF, MU, FEYE and ISIS.
MU: 33.09 (+1.27), HLF: 52.46 (+1.90), PBR: 11.70 (+0.38), FEYE: 33.99 (+0.36), ISIS: 46.06 (+0.18)